Although federal officials pulled the plug on a trial testing a Lilly antibody drug for people hospitalized with COVID-19, other studies for the therapy are continuing on populations that could become big markets.
The discontinuation of the study, along with the release of third-quarter earnings that fell short of analysts’ expectations, caused Lilly shares to fall 3.5% in premarket trading Tuesday.
Eli Lilly and Co. on Thursday announced that it has agreed to acquire Disarm Therapeutics, a private biotechnology company that is developing therapies that could be used to treat multiple sclerosis, glaucoma, Alzheimer’s disease and ALS.
Lilly said it is reviewing safety data that caused federal researchers to pause a trial of the company’s COVID-19 antibody treatment in hospitalized patients. Other trials using lower doses of the drug outside the hospital will continue.
Indianapolis-based Eli Lilly and Co. said it made the decision on recommendation of the Data and Safety Monitoring Board “out of an abundance of caution.”
Experimental antibody drugs like the one President Trump was given and the one Eli Lilly is developing are among the most promising therapies being tested for treating and preventing coronavirus infections. Here’s how they work.
Shares of Lilly jumped 3.7%, or $5.41, to $149.54 in afternoon trading following the company’s morning announcement that it has asked the U.S. government to allow emergency use of the therapy to treat the disease.
Eli Lilly and Co. says it has asked the U.S. government to allow emergency use of an experimental antibody therapy based on positive early results from a study.
A long-simmering dispute between Eli Lilly and Co. and safety-net hospitals across the nation over the price of prescription drugs has reached the boiling point.
It’s a big pivot for organizations that traditionally create high-visibility fall projects to call attention to volunteerism and community service. In the process, they help dozens of neighborhood groups and scores of not-for-profits, from the United Way of Central Indiana to Keep Indianapolis Beautiful.
The medical school said it is testing the use of tezampanel, an experimental drug for migraines developed by Indianapolis-based drugmaker Eli Lilly and Co., to treat opioid withdrawal syndrome and other addictions and mental illnesses.
Wednesday’s results come from 450 people in a mid-stage study testing an antibody jointly developed by Lilly and the Canadian company AbCellera in people with COVID-19 symptoms not severe enough to warrant hospitalization.
Eli Lilly announced the results Monday from a 1,000-person study sponsored by the U.S. National Institute of Allergy and Infectious Diseases.
Lilly and partner Boehringer Ingelheim published results from a trial showing the drug cut the risk of cardiovascular hospitalizations or death by 25%, compared to placebo in heart failure patients.
With a coronavirus vaccine still months off, companies—including Indianapolis-based Eli Lilly and Co.—are rushing to test what might be the next best thing: drugs that deliver antibodies to fight the virus.
The Indianapolis-based drugmaker said it will enroll about 2,400 residents and staff of nursing homes to test an antibody it is developing with a Canadian biotech. Nursing homes account for about 40% of U.S. deaths from COVID-19.
An experimental blood test from Indianapolis-based Eli Lilly and Co. was highly accurate at distinguishing people with Alzheimer’s disease from those without it in several studies, boosting hopes that there soon may be a simple way to help diagnose the condition.
Under the agreement, researchers will study patients who used Lilly autoimmune therapies that are under consideration for the treatment of other autoimmune diseases, including inflammatory bowel disease and psoriasis.
In the past seven years, the drugmaker has received tax breaks worth nearly $40 million in exchange for investing more than $500 million at its Indianapolis properties.
Aarti Shah oversees Lilly’s global information technology, information security, advanced analytics and data sciences, and digital health.
